In September 2022, Eli Lilly published the results of its preclinical studies on LY3437943 in the journal Cell Metabolism, in an article titled "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." In vitro and in vivo validation of the triple agonist effect of LY3437943: Eli Lilly's research results show that LY3437943 demonstrates superior weight loss effects compared to GLP-1 receptor (GLP-1R) selective agonists (GLP-1 RA), GLP-1R and GCGR dual agonists (Cotadutide or 05677), and GLP-1R and GIPR dual agonists
To test the hunch, the team pulled records for more than 42,000 adults
[10] The authors of that study note that "berberine exhibited an identical effect in the regulation of glucose metabolism" (as measured on HbA1c and blood glucose levels when fasted and after eating), it even regulated lipid metabolism more than metformin
More information on how Google Analytics handles user data can be found in the Google privacy policy: Order processing We have signed an order processing agreement with Google and fully implement the strict requirements of the German data privacy authorities when using Google Analytics
.webp)
.webp)
